Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABOSTO:BOUL -0.57%47 Debt-to-EBITDA is 94.71 as of Jun. 2026, which is 5857% above its 10-year median of 1.59. GuruFocus rates OSTO:BOUL with a GF Score™ of 47/100 and a GF Value™ of kr6.43 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 93.02% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Boule Diagnostics AB's Debt-to-EBITDA or its related term are showing as below:
OSTO:BOUL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.36 Med: 1.59 Max: 12.03
Current: 12.03
During the past 13 years, the highest Debt-to-EBITDA Ratio of Boule Diagnostics AB was 12.03. The lowest was -5.36. And the median was 1.59.
OSTO:BOUL's Debt-to-EBITDA is ranked worse than 93.02% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs OSTO:BOUL: 12.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Boule Diagnostics AB Debt-to-EBITDA Related Terms
Boule Diagnostics AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:BOUL vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Boule Diagnostics AB (OSTO:BOUL) has a Debt-to-EBITDA of 94.71 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Boule Diagnostics AB. This is 5857% above median its historical median of 1.59. According to the industry distribution chart, Boule Diagnostics AB ranks #440 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 93%.
Is Boule Diagnostics AB's Debt-to-EBITDA too high?
Boule Diagnostics AB's current Debt-to-EBITDA of 94.71 is 5857% above median its 10-year median of 1.59. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Boule Diagnostics AB's value of 94.71 is 5675% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #440 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #440 out of 473 companies for Debt-to-EBITDA. This places Boule Diagnostics AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Boule Diagnostics AB's value of 94.71 is 5675% above this benchmark. While the company's 10-year median is 1.59 vs. the industry median of 1.64, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Debt-to-EBITDA of 94.71 is 5675% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Boule Diagnostics AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Debt-to-EBITDA is 94.71, which is 5857% above median its own 10-year median of 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Boule Diagnostics AB (OSTO:BOUL) is currently considered Possible Value Trap. The stock's GF Value™ is kr6.43, compared to a current price of kr3.50 — trading 45.6% below its estimated fair value. The current Debt-to-EBITDA is 94.71, which is 5857% above median its 10-year median of 1.59 and 5675% above the Medical Devices & Instruments industry median of 1.64. Boule Diagnostics AB's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Boule Diagnostics AB (OSTO:BOUL), the current Debt-to-EBITDA is 94.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (OSTO:BOUL) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr3.50 is trading 45.6% below its estimated GF Value™ of kr6.43.
GuruFocus considers Boule Diagnostics AB to be Possible Value Trap.
Key valuation signals for OSTO:BOUL:
Debt-to-EBITDA: 94.71 (5857% above median its 10-year median of 1.59)
GF Value™: kr6.43 vs. price of kr3.50 (45.6% below fair value)
Industry Position: 5675% above the Medical Devices & Instruments median (#440 of 473)
No single metric tells the full story. See the OSTO:BOUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for OSTO:BOUL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:BOUL has been successfully added to your 
